Trial Profile

A Phase III Randomized, Controlled Study of Equecabtagene Autoleucel Injection in Subjects With Lenalidomide-Refractory R/R Multiple Myeloma

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 26 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Equecabtagene autoleucel (Primary) ; Bortezomib; Daratumumab; Dexamethasone; Pomalidomide
Indications Multiple myeloma
Focus Registrational; Therapeutic Use
Acronyms FUMANBA-03
Sponsors Nanjing IASO Biotechnology

Most Recent Events

05 Jul 2024 According to an IASO BioMed media release, On March 28, 2024, FUCASO received the investigational new drug (IND) application for treating RRMM patients who have undergone 1-2 lines of prior therapies and are refractory to lenalidomide.
20 Jun 2024 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com